News Releases
Alcon Receives FDA Approval of Pazeo Solution for Ocular Allergy Itch Relief
Alcon, the global leader in eye care and a division of Novartis, has received approval from the U.S. Food and Drug Administration (FDA) of Pazeo™ (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of ocular itching associated with allergic conjunctivitis.
FDA Approves Treatment for Children With Allergic Rhinitis
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved QNASL® (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age.
FDA Approves New Rx for Grass Pollen-Induced Allergic Rhinitis
The FDA has approved a new medication for those with symptoms caused by grass pollen allergy.
Greer Announces FDA Approval of Oralair for Grass Pollen Allergy
The FDA has approved a new medication to treat grass pollen allergies.